Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2549105 | 0.88 | TRPM4 (0.35) | TRPM4ALDH1A1HSD17B10CYP1B1HIF1A | |
| SCHEMBL2548800 | 0.83 | TRPM4 (0.42) | TRPM4ALDH1A1HSD17B10CYP1B1HIF1A | |
| SCHEMBL2547962 | 0.78 | HTR2A (0.39) | TRPM4ALDH1A1HSD17B10CYP1B1HIF1A | |
| SCHEMBL2550357 | 0.78 | ALDH1A1 (0.39) | ALDH1A1HSD17B10CYP1A2HPGDCYP2A6 | |
| SCHEMBL2882747 | 0.74 | ALDH1A1 (0.32) | ALDH1A1TSHRTDP1TAAR1MAPK1 | |
| SCHEMBL8406649 | 0.72 | ALDH1A1 (0.50) | TRPM4ALDH1A1HSD17B10CYP1B1HIF1A | |
| SCHEMBL28429887 | 0.69 | TRPM4 (0.46) | TRPM4ALDH1A1HSD17B10CYP1B1HIF1A | |
| SCHEMBL2879337 | 0.69 | TRPM4 (0.46) | TRPM4ALDH1A1HSD17B10CYP1B1HIF1A | |
| SCHEMBL2542560 | 0.67 | ACHE (0.38) | ALDH1A1TSHRTDP1HTR2AMAPT | |
| SCHEMBL2552546 | 0.67 | CYP2A6 (0.44) | ALDH1A1HSD17B10HIF1ACYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552928-B1 | A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST. | CHROMAFORA AB (SE) | 2015-04-15 | — | — | EP | disclosed |
| US-8735629-B2 | Process for the reduction of a tertiary phosphine oxide to the corresponding tertiary phosphine in the presence of a catalyst and use of a tertiary phosphine for reducing a tertiary phosphine oxide in the presence of a catalyst | CHROMAFORA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| US-8426647-B2 | — | — | 2013-04-23 | — | — | US | disclosed |
| US-20130012725-A1 | PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST | CHROMAFORA AB (SE) | 2013-01-10 | — | — | US | disclosed |
| US-7847126-B2 | prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example | LANXESS DEUTSCHLAND GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20070299273-A1 | prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example | LANXESS DEUTSCHLAND GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| US-7230136-B2 | Reacting phosphorus halide with organomagnesium compound in presence of copper compound | LANXESS DEUTSCHLAND GMBH (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20030229240-A1 | Reacting phosphorus halide with organomagnesium compound in presence of copper compound | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| EP-1354886-A1 | Process for the preparation of tertiary phosphines | Bayer Aktiengesellschaft (DE) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012725-A1 | PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST | PSPH, PNPO, PHOSPHO1 | TRPM4 4136/4885ALDH1A1 2830/4885HSD17B10 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.